Item 2.02. Results of Operations and Financial Condition.
In connection with the press release described in Item 8.01 below, on January 9,
2023, Rigel Pharmaceuticals, Inc. ("Rigel") provided, on a preliminary and
unaudited basis, certain estimated financial results for its fourth quarter and
fiscal year ended December 31, 2022. The preliminary estimates are based on
currently available information and do not present all necessary information for
a complete understanding of Rigel's financial condition as of December 31, 2022
or Rigel's results of operations for the fourth quarter or year ended December
31, 2022.
Item 8.01. Other Events.
On January 9, 2023, Rigel issued a press release titled "Rigel Pharmaceuticals
Provides Business Update." A copy of the press release is attached hereto as
Exhibit 99.1 and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Description
99.1 Press Release, dated January 9, 2023, titled "Rigel Pharmaceuticals
Provides Business Update"
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
© Edgar Online, source Glimpses